ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving Care and Reducing Cost Study (ICRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02364544
Recruitment Status : Completed
First Posted : February 18, 2015
Last Update Posted : March 23, 2017
Sponsor:
Collaborators:
University of Pittsburgh
Boston University
Dartmouth-Hitchcock Medical Center
Information provided by (Responsible Party):
John Kane, Northwell Health

Brief Summary:
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction. This will be done by fostering innovation in the use of technology and by training and deploying a new cadre of personnel in the behavioral health field: Mental Health/Health Technology (MH/HT) Case Managers.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Psychosis NOS Behavioral: Relapse Prevention Plan Behavioral: Daily Support Website Behavioral: Computer CBT for voices and paranoia Behavioral: FOCUS Other: Prescriber Decision Assistant Not Applicable

Detailed Description:

The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while providing better care, better health and increased patient satisfaction. This will be done by fostering innovation in the use of technology and by training and deploying a new cadre of personnel in the behavioral health field: Mental Health/Health Technology (MH/HT) Case Managers. The specific treatments we propose to use are evidence based, but their dissemination has been limited because of lack of trained personnel and cost. The model we propose, the Health Technology Program (HTP), will address these problems through use of the web and mobile phone based training and interventions.

The components of the HTP program that are being tested in the pilot program include: 1) evidence-based pharmacological treatment facilitated by a web-based prescriber decision support system-Prescriber Decision Assistant (PDA) 2) brief, in-person, relapse prevention counseling with supplemental web-based learning modules, 3) a daily support website that offers web- and phone-based resources to support persons with schizophrenia and their family members or others. The resources include a patient and family Psycho-Education Treatment program, which includes electronic peer groups facilitated by mental health professionals, providing medication reminders via web and phone, and conducting monitoring of early warning signs of relapse via web and phone 4) an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia 5) a web-based, self-administered cognitive-behavioral therapy (CBT) program for the management of hallucinations. All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 461 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Improving Care and Reducing Cost (ICRC) Program
Study Start Date : April 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Health Technology Program

The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program

All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference.

Behavioral: Relapse Prevention Plan
brief, in-person, relapse prevention counseling with supplemental web-based learning modules,

Behavioral: Daily Support Website
web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions

Behavioral: Computer CBT for voices and paranoia
A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies

Behavioral: FOCUS
an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia

Other: Prescriber Decision Assistant
is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response




Primary Outcome Measures :
  1. Total Number of Hospitalization and Emergency Room Visits [ Time Frame: Baseline, Month 1, Month2, Month 3, Month4, Month 5, and Month 6 ]
    Captures the number of hospital and ER visits each month


Secondary Outcome Measures :
  1. Service Utilization Resource Form [ Time Frame: Baseline, month 3, month 6 ]
    Captures services received in the last 30 days

  2. Change from Baseline Heinrich's Quality of Life Scale [ Time Frame: Baseline and month 6 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Age 18 to 60, (patients age 51-60 require review from the coordinating site)

    • Clinical diagnosis of:

      • schizophrenia
      • schizoaffective disorder
      • psychosis NOS
    • Has had two or more inpatient hospitalizations for treatment of a psychotic disorder
    • Currently in the hospital or up to 30 days of inpatient hospitalization for a psychotic disorder

      o If patients are sent to a partial, or day hospital following an inpatient hospitalization, the 30 day window begins at the time of discharge from the day or partial hospital

    • Any ethnicity
    • Ability to participate in research assessments in English
    • Ability to provide fully informed consent

Exclusion Criteria:

  • • Individuals who cannot understand what research participation entails, or correctly answer the questions about research participation that are part of the Study Information Review and provide fully informed consent will be excluded

    • More than 30 days since discharge from a psychiatric hospitalization
    • Any other serious medical condition that in the opinion of the investigator would seriously impair functioning making the patient unsuitable for the trial
    • Patients who would likely find it burdensome and/or have difficulty sustaining the use of a laptop computer and /or smart phone due to issues of security, consistent connectivity or other factors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02364544


Locations
United States, Florida
Henderson Mental Health Center
Ft Lauderdale, Florida, United States, 33319
United States, Indiana
Community Mental Health Center, Inc.
Lawrenceburg, Indiana, United States, 47025
United States, Michigan
Cherry Street
Grand Rapids, Michigan, United States, 49503
United States, Missouri
UMKC School of Pharmacy
Kansas City, Missouri, United States, 64108
Burrell Behavioral Health
Springfield, Missouri, United States, 65802
United States, New Hampshire
The Mental Health Center of Greater Manchester
Manchester, New Hampshire, United States, 03101
United States, New Mexico
University of New Mexico Department of Psychiatry UNM Health Sciences Center
Albuquerque, New Mexico, United States, 87131
United States, Oregon
PeaceHealth Oregon/Lane County Behavioral Health Services
Eugene, Oregon, United States, 97401
Sponsors and Collaborators
Northwell Health
University of Pittsburgh
Boston University
Dartmouth-Hitchcock Medical Center
Investigators
Principal Investigator: John Kane Northwell Health

Responsible Party: John Kane, Senior Vice President, Behavioral Health Services, Northwell Health
ClinicalTrials.gov Identifier: NCT02364544     History of Changes
Other Study ID Numbers: ICRC
First Posted: February 18, 2015    Key Record Dates
Last Update Posted: March 23, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Schizophrenia
Psychotic Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders